MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.

Jacks T, Smith R, Judith F, Schleim K, Frazier E, Chen H, Krupa D, Hora D Jr, Nargund R, Patchett A, Hickey G

Endocrinology1 Dec 1996Cited by 31 (Europe PMC)

PMID8940347DOI10.1210/endo.137.12.8940347PepBankPUB-08940347

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In beagles, oral MK-0677 increased peak GH at the low dose.
In plain wordsIn dogs, oral MK-0677 increased peak GH compared with water placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreasePeak GH at oral low dose
Study
dogn = 8
beagles
Comparator
water placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.25 mg/kg · oralAs given in this study (dog).
Source sentences
Summary
After oral administration in a balanced eight-dog crossover study, treatment with MK-0677 significantly increased peak GH concentrations, with a 5.3-fold increase (mean +/- SEM, 10.5 +/- 1.9 ng/ml) at the 0.25 mg/kg dose
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034701
02AnimalAnimal study (in vivo)Efficacy outcome
In beagles, oral MK-0677 increased peak GH at the middle dose.
In plain wordsIn dogs, oral MK-0677 increased peak GH compared with water placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreasePeak GH at oral middle dose
Study
dogn = 8
beagles
Comparator
water placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.50 mg/kg · oralAs given in this study (dog).
Source sentences
Summary
a 9.0-fold increase (18.0 +/- 3.3 ng/ml) at the 0.50 mg/kg dose
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034702
03AnimalAnimal study (in vivo)Efficacy outcome
In beagles, oral MK-0677 increased peak GH at the high dose.
In plain wordsIn dogs, oral MK-0677 increased peak GH compared with water placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreasePeak GH at oral high dose
Study
dogn = 8
beagles
Comparator
water placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1.0 mg/kg · oralAs given in this study (dog).
Source sentences
Summary
and a 15.8-fold increase (31.6 +/- 5.8 ng/ml) at the 1.0 mg/kg dose.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034703
04AnimalAnimal study (in vivo)Efficacy outcome
In beagles, oral MK-0677 increased total GH release versus water placebo.
In plain wordsIn dogs, oral MK-0677 increased total GH release compared with water placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseOral GH area under curve
Study
dogn = 8
beagles
Comparator
water placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · oralAs given in this study (dog).
Source sentences
Summary
Total GH release, expressed as the area under the curve, showed similar significant increases over the effect of the water placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034704
05AnimalAnimal study (in vivo)Efficacy outcome
In beagles, single-dose oral MK-0677 produced a GH peak and prolonged GH elevation.
In plain wordsIn dogs, oral MK-0677 produced a GH peak and prolonged GH elevation.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseGH peak after single oral dose
Study
dogn = 3
beagles
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg · oralAs given in this study (dog).
Measurements
mean GH peak
27.6 ng/ml
oral
peak time
120 min
oral
elevation duration
360 min
oral
Source sentences
Summary
A single oral 1 mg/kg dose in three dogs induced a mean GH peak of 27.6 +/- 1.5 ng/ml at 120 min, and GH levels remained elevated up to 360 min after treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034705
06AnimalAnimal study (in vivo)Efficacy outcome
In beagles, oral MK-0677 increased IGF-I after treatment.
In plain wordsIn dogs, IGF-I increased after oral MK-0677.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseOral IGF-I
Study
dogn = 3
beagles
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg · oralAs given in this study (dog).
Measurements
IGF-I increase
30%
480 min
Source sentences
Summary
Insulin-like growth factor I (IGF-I) levels were significantly increased by 30% at 480 min after treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A single oral 1 mg/kg dose in three dogs induced a mean GH peak of 27.6 +/- 1.5 ng/ml at 120 min, and GH levels remained elevated up to 360 min after treatment.
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034706
07AnimalAnimal study (in vivo)Efficacy outcome
In beagles, oral MK-0677 increased cortisol over pretreatment levels.
In plain wordsIn dogs, cortisol increased from pretreatment levels after oral MK-0677.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseOral cortisol
Study
dogn = 3
beagles
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
1 mg/kg · oralAs given in this study (dog).
Source sentences
Summary
Cortisol levels were increased 2.4-fold over pretreatment levels.
2 context sentences(design, population, supporting numbers)
Summary · context
A single oral 1 mg/kg dose in three dogs induced a mean GH peak of 27.6 +/- 1.5 ng/ml at 120 min, and GH levels remained elevated up to 360 min after treatment.
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034707
08AnimalAnimal study (in vivo)Efficacy outcome
In beagles, intravenous MK-0677 increased peak GH versus saline control.
In plain wordsIn dogs, intravenous MK-0677 increased peak GH compared with saline control.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIntravenous peak GH
Study
dogn: not reported in source
beagles
Comparator
saline control
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.25 mg/kg · intravenousAs given in this study (dog).
Source sentences
Summary
After i.v. administration, compared to the saline control group which had a mean (+/- SEM) serum GH peak of 3.8 +/- 0.7 ng/ml, MK-0677 at 0.25 mg/kg significantly increased (P < 0.05) peak GH concentrations 20.4-fold (77.4 +/- 13.7 ng/ml).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034708
09AnimalAnimal study (in vivo)Efficacy outcome
In beagles, intravenous MK-0677 increased total GH release versus saline control.
In plain wordsIn dogs, intravenous MK-0677 increased total GH release compared with saline control.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIntravenous GH area under curve
Study
dogn: not reported in source
beagles
Comparator
saline control
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.25 mg/kg · intravenousAs given in this study (dog).
Source sentences
Summary
Total GH release, expressed as the area under the curve, showed a similar increase.
2 context sentences(design, population, supporting numbers)
Summary · context
After i.v. administration, compared to the saline control group which had a mean (+/- SEM) serum GH peak of 3.8 +/- 0.7 ng/ml, MK-0677 at 0.25 mg/kg significantly increased (P < 0.05) peak GH concentrations 20.4-fold (77.4 +/- 13.7 ng/ml).
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034709
10AnimalAnimal study (in vivo)Efficacy outcome
In beagles, intravenous MK-0677 produced a rapid GH peak and sustained elevation.
In plain wordsIn dogs, intravenous MK-0677 produced a rapid GH peak and sustained elevation.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIntravenous GH time course
Study
dogn: not reported in source
beagles
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.25 mg/kg · intravenousAs given in this study (dog).
Measurements
peak time
10 min
intravenous
elevation duration
180 min
intravenous
Source sentences
Summary
The mean peak GH level was recorded 10 min after treatment, with GH levels elevated up to 180 min after treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
After i.v. administration, compared to the saline control group which had a mean (+/- SEM) serum GH peak of 3.8 +/- 0.7 ng/ml, MK-0677 at 0.25 mg/kg significantly increased (P < 0.05) peak GH concentrations 20.4-fold (77.4 +/- 13.7 ng/ml).
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034710
11AnimalAnimal study (in vivo)Efficacy outcome
In beagles, intravenous MK-0677 increased IGF-I.
In plain wordsIn dogs, IGF-I increased after intravenous MK-0677.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIntravenous IGF-I
Study
dogn: not reported in source
beagles
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.25 mg/kg · intravenousAs given in this study (dog).
Source sentences
Summary
IGF-I levels were significantly elevated by 25% 360 min after the administration of MK-0677.
2 context sentences(design, population, supporting numbers)
Summary · context
After i.v. administration, compared to the saline control group which had a mean (+/- SEM) serum GH peak of 3.8 +/- 0.7 ng/ml, MK-0677 at 0.25 mg/kg significantly increased (P < 0.05) peak GH concentrations 20.4-fold (77.4 +/- 13.7 ng/ml).
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034711
12AnimalAnimal study (in vivo)Efficacy outcome
In beagles, intravenous MK-0677 increased cortisol over pretreatment levels.
In plain wordsIn dogs, cortisol increased from pretreatment levels after intravenous MK-0677.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIntravenous cortisol
Study
dogn: not reported in source
beagles
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
0.25 mg/kg · intravenousAs given in this study (dog).
Source sentences
Summary
Cortisol levels were increased 2.3-fold over pretreatment levels.
2 context sentences(design, population, supporting numbers)
Summary · context
After i.v. administration, compared to the saline control group which had a mean (+/- SEM) serum GH peak of 3.8 +/- 0.7 ng/ml, MK-0677 at 0.25 mg/kg significantly increased (P < 0.05) peak GH concentrations 20.4-fold (77.4 +/- 13.7 ng/ml).
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034712
13AnimalAnimal study (in vivo)Efficacy outcome
In beagles, insulin was higher after MK-0677 but remained within the normal range.
In plain wordsIn dogs, insulin was higher after MK-0677 but remained within the normal range.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseInsulin
Study
dogn: not reported in source
beagles
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Insulin and glucose levels were higher, LH and PRL levels were unaltered, and T4 levels were marginally lower; the levels of each of these hormones remained within the normal ranges for dogs throughout the experiment.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034713
14AnimalAnimal study (in vivo)Efficacy outcome
In beagles, glucose was higher after MK-0677 but remained within the normal range.
In plain wordsIn dogs, glucose was higher after MK-0677 but remained within the normal range.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseGlucose
Study
dogn: not reported in source
beagles
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Insulin and glucose levels were higher, LH and PRL levels were unaltered, and T4 levels were marginally lower; the levels of each of these hormones remained within the normal ranges for dogs throughout the experiment.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034714
15AnimalAnimal study (in vivo)Efficacy outcome
In beagles, MK-0677 did not alter LH levels.
In plain wordsIn dogs, MK-0677 did not change LH levels.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeLH
Study
dogn: not reported in source
beagles
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Insulin and glucose levels were higher, LH and PRL levels were unaltered, and T4 levels were marginally lower; the levels of each of these hormones remained within the normal ranges for dogs throughout the experiment.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034715
16AnimalAnimal study (in vivo)Efficacy outcome
In beagles, MK-0677 did not alter PRL levels.
In plain wordsIn dogs, MK-0677 did not change PRL levels.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changePRL
Study
dogn: not reported in source
beagles
Outcome group
Pituitary hormones · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Insulin and glucose levels were higher, LH and PRL levels were unaltered, and T4 levels were marginally lower; the levels of each of these hormones remained within the normal ranges for dogs throughout the experiment.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034716
17AnimalAnimal study (in vivo)Efficacy outcome
In beagles, T4 was marginally lower after MK-0677 but remained within the normal range.
In plain wordsIn dogs, T4 was marginally lower after MK-0677 but remained within the normal range.
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseT4
Study
dogn: not reported in source
beagles
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Insulin and glucose levels were higher, LH and PRL levels were unaltered, and T4 levels were marginally lower; the levels of each of these hormones remained within the normal ranges for dogs throughout the experiment.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of MK-0677 on serum GH and other hormones after oral and iv single dose administrations in beagles were evaluated.
Report a problemFND-0894034717

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.